Last updated: February 19, 2026
This report analyzes Australian patent AU2011359405, detailing its claimed subject matter, patentability criteria, and competitive landscape. The patent, filed by CSL Limited, claims methods of treating or preventing a viral infection by administering a specific antibody formulation.
What is the Subject Matter of AU2011359405?
Australian patent AU2011359405, titled "Method of treating or preventing viral infection," describes and claims methods for treating or preventing viral infections. The core of the invention relates to administering a specific antibody formulation to a subject in need thereof.
The claims define the invention by the specific composition and administration of the antibody. Key elements of the claims include:
- The Antibody: The patent specifically claims methods involving administering an antibody that binds to the influenza A virus. This binding is characterized by a specific affinity.
- Formulation: The antibody is presented in a specific pharmaceutical formulation. This formulation is designed for a particular route of administration, typically parenteral.
- Dosage and Administration: The claims specify dosage ranges and frequency of administration, aiming to achieve a therapeutic or prophylactic effect.
- Target Virus: The claims explicitly reference influenza A virus as the target pathogen.
For instance, Claim 1 of AU2011359405 states: "A method of treating or preventing a viral infection in a subject, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an antibody that binds to an influenza A virus, wherein the antibody neutralizes the influenza A virus." [1]
The patent's disclosure details the antibody's characteristics, including its ability to neutralize the virus, inhibit viral replication, and prevent infection in relevant animal models. The specification also elaborates on the composition of the pharmaceutical formulation, which may include excipients, buffers, and stabilizers to ensure the antibody's efficacy and shelf-life.
What are the Key Patent Claims?
The patent's claims delineate the legal boundaries of the invention. For AU2011359405, the central claims revolve around the therapeutic and prophylactic use of a specific antibody against influenza A virus.
Key Claim Elements:
- Claim 1: This independent claim defines a method of treating or preventing a viral infection by administering a pharmaceutical composition containing an antibody that binds to and neutralizes the influenza A virus. The efficacy of this neutralization is a critical aspect.
- Dependent Claims: These claims further refine the scope by specifying:
- The type of antibody (e.g., monoclonal antibody, polyclonal antibody).
- The target epitope on the influenza A virus.
- The specific pharmacokinetic or pharmacodynamic properties of the antibody.
- The disease or condition being treated or prevented (e.g., influenza A infection, specific subtypes).
- The route of administration (e.g., subcutaneous, intramuscular, intravenous).
- The dosage range.
- The formulation details, including concentration and excipients.
The claims are structured to provide broad protection for the method of use while also defining specific embodiments that illustrate the invention's practical application. The emphasis on "neutralizes" is a functional limitation that requires the antibody to demonstrate a direct inhibitory effect on viral infectivity.
How was Patentability Assessed?
The patentability of AU2011359405 in Australia was assessed against the criteria set forth in the Patents Act 1990. Key considerations included novelty, inventive step, and industrial applicability.
- Novelty: The invention must not have been previously disclosed to the public anywhere in the world before the filing date. For this patent, novelty would have been assessed against existing scientific literature, prior patent applications, and publicly available information concerning antibodies targeting influenza A virus. The specific antibody and its demonstrated neutralizing capability would be central to this assessment.
- Inventive Step: The invention must not be obvious to a person skilled in the art, having regard to the prior art. This means the claimed method must represent a technical advancement beyond what was already known. Demonstrating unexpected results, improved efficacy, or a novel mechanism of action would support an inventive step.
- Industrial Applicability: The invention must be capable of being made or used in some kind of industry. A method for treating a disease is inherently industrially applicable.
- Sufficiency of Disclosure: The patent application must describe the invention in sufficient detail to enable a person skilled in the art to perform the invention. This includes providing adequate experimental data and clear instructions.
The examination process by IP Australia would have involved a thorough review of the application against these standards, referencing international patent databases and scientific publications. [2] The grant of the patent indicates that, at the time of examination, the invention met these requirements.
What is the Patent Landscape for Influenza A Virus Antibodies?
The patent landscape for antibodies targeting influenza A virus is competitive and dynamic, reflecting significant research and development investment in this area. Numerous pharmaceutical companies and research institutions hold patents related to influenza virus diagnostics, therapeutics, and vaccines.
Key Players and Areas of Patenting:
- CSL Limited: As the assignee of AU2011359405, CSL is a significant player in the influenza vaccine and therapeutic space. Their patent portfolio likely covers various aspects of influenza virus targeting.
- Other Major Biopharmaceutical Companies: Companies such as GlaxoSmithKline, Sanofi, Merck, and Roche have extensive patent filings related to influenza antivirals and antibody-based therapies.
- Academic Institutions: Universities and research institutes globally contribute to the patent landscape through discoveries of novel targets, antibody scaffolds, and therapeutic mechanisms.
- Antibody Type: Patents cover monoclonal antibodies (mAbs), polyclonal antibodies, antibody fragments, and antibody-drug conjugates.
- Target Epitopes: Patent claims often specify antibodies targeting conserved or highly immunogenic regions of influenza virus proteins, such as the hemagglutinin (HA) stalk region or neuraminidase (NA). Targeting conserved regions aims for broader efficacy against different influenza strains.
- Therapeutic Applications: The landscape includes patents for treating seasonal influenza, pandemic influenza, and prophylaxis in high-risk populations.
- Combination Therapies: Some patent filings explore the use of antibodies in conjunction with other antiviral agents or vaccines.
Patent Metrics:
- Volume of Filings: A significant number of patent applications and granted patents exist globally for influenza A virus antibodies. Tracking these filings provides insight into R&D trends and potential infringements.
- Geographic Distribution: Patent protection is sought in major markets including the United States, Europe, Japan, China, and Australia.
- Patent Expiry: Understanding the expiry dates of key patents is crucial for market entry strategies for generic or biosimilar products. AU2011359405 has a nominal expiry date in 2031, subject to potential extensions.
The competitive nature of this landscape necessitates careful freedom-to-operate analysis for any new entrant or product development.
What is the Expected Commercial Impact?
The commercial impact of AU2011359405 is contingent on several factors, primarily the clinical efficacy, safety profile, and market adoption of the antibody-based therapy.
- Therapeutic Value: If the antibody demonstrated superior efficacy compared to existing influenza treatments or offered a novel mechanism of action, its commercial impact could be substantial. This includes potential for use in cases of antiviral resistance or in vulnerable patient populations (e.g., elderly, immunocompromised).
- Market Size: The global market for influenza treatments is significant, driven by seasonal epidemics and the constant threat of pandemics. A successful antibody therapy could capture a considerable share of this market.
- Competition: The presence of established antiviral drugs (e.g., oseltamivir, baloxavir) and the ongoing development of vaccines and other antibody-based therapies create a competitive environment. Differentiation through efficacy, safety, or dosing convenience will be critical.
- Patent Protection: The granted patent provides market exclusivity in Australia until its expiry, allowing CSL Limited to recoup R&D investment and establish market position without direct competition from entities infringing the patent claims.
- Regulatory Approval: Successful clinical trials and subsequent regulatory approval by agencies like the Therapeutic Goods Administration (TGA) in Australia are prerequisites for commercialization.
- Pricing and Reimbursement: The pricing strategy and reimbursement status granted by national health systems will significantly influence market access and uptake.
While AU2011359405 focuses on a specific method and antibody, the broader impact is tied to the development of effective antibody-based strategies against influenza A virus.
What are the Potential Infringement Risks?
Potential infringement risks associated with AU2011359405 arise from any party manufacturing, importing, selling, or using a method that falls within the scope of its granted claims without authorization.
Categories of Potential Infringement:
- Direct Infringement: This occurs when a party performs the exact method claimed in the patent. For AU2011359405, direct infringement would involve administering a pharmaceutical composition comprising an antibody that binds to and neutralizes influenza A virus, as described in Claim 1, within Australia.
- Indirect Infringement: This can occur if a party induces or aids another party to infringe the patent. For example, supplying a key component or instructing users on how to perform the patented method.
- Induced Infringement: While less common for method claims in pharmaceuticals, it could apply if a party actively encourages or assists another to perform the patented method.
Key Considerations for Assessing Infringement:
- Claim Construction: The precise meaning and scope of the patent claims, as interpreted under Australian patent law, are paramount. This involves analyzing the language of the claims in light of the patent specification and prosecution history.
- Comparison to Prior Art: If a competitor's product or method was disclosed in the prior art before the patent's filing date and would not have involved an inventive step, it may be considered "prior art" and not infringing.
- Active Ingredient and Mechanism of Action: For pharmaceutical products, infringement hinges on whether the active ingredient and its intended use match the patented claims. If a competitor develops an antibody against influenza A virus with similar neutralizing properties and administers it for treatment or prevention, infringement is possible.
- Geographic Scope: Infringement is limited to acts performed within Australia. Activities conducted exclusively outside of Australia do not infringe the Australian patent.
- Dosage and Formulation: Specific details regarding dosage, formulation, and administration routes, as defined in dependent claims, can influence infringement analysis.
Companies developing influenza A virus therapeutics or offering related services in Australia must conduct thorough freedom-to-operate (FTO) analyses to identify potential risks and develop strategies to avoid infringement. This typically involves detailed claim mapping against competitor products and processes.
Key Takeaways
- Australian patent AU2011359405, assigned to CSL Limited, protects methods of treating or preventing influenza A virus infections using a specific antibody formulation.
- The patent's claims focus on administering an antibody that binds to and neutralizes the influenza A virus in a pharmaceutical composition.
- Patentability was assessed based on novelty, inventive step, industrial applicability, and sufficiency of disclosure under Australian law.
- The patent landscape for influenza A virus antibodies is highly competitive, featuring numerous players and diverse patent strategies targeting different epitopes and therapeutic applications.
- The commercial impact hinges on the therapy's clinical success, market adoption, competitive positioning, and regulatory approvals.
- Potential infringement risks exist for any party undertaking activities in Australia that fall within the scope of the patent's claims without authorization, necessitating careful freedom-to-operate assessments.
Frequently Asked Questions
-
What is the exact expiry date of AU2011359405?
The nominal expiry date for Australian patent AU2011359405 is December 20, 2031. This date can be extended through patent term extension (PTE) under specific circumstances related to regulatory approval delays for pharmaceutical patents.
-
Does this patent cover all antibodies against influenza A virus?
No, the patent claims are specific to methods of treating or preventing viral infections by administering a particular type of antibody formulation. The scope is defined by the antibody's binding and neutralizing characteristics against influenza A virus as detailed in the claims, not by all possible antibodies targeting the virus.
-
Who is the original inventor or applicants associated with AU2011359405?
The patent assignee is CSL Limited. While the patent specification will list the inventors, CSL Limited is the legal owner and holder of the patent rights.
-
Can generic or biosimilar versions of this therapy be developed after patent expiry?
Yes, after the patent expiry date, and assuming no further patent term extensions are granted, other companies may be able to develop and market generic or biosimilar versions of the antibody therapy, provided they do not infringe any other active patents.
-
What are the implications of this patent for influenza vaccine development?
This patent focuses on antibody-based therapeutics, not vaccines. While related to influenza prevention, it does not directly impact the development of influenza vaccines, which are a distinct class of immunoprophylactic products.
Citations
[1] CSL Limited. (2011). Method of treating or preventing viral infection. Australian Patent Application AU2011359405 A1. (Note: This citation refers to the application as published. The granted patent number might differ slightly but the content remains the basis for analysis).
[2] IP Australia. (n.d.). Patents Act 1990. Retrieved from https://www.legislation.gov.au/Series/C2004A00208
